Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 1,985 | 0.82 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 11932
Sealed predictions
- MGP in dopamine neurons, braak+0.48 (p 0.194) → +0.00 (p 1.000)receipt 11939
Swarm cases
receipt 11939: MGP in dopamine neurons, braak
- power
- full sample +0.30 (p 0.225, n 18), 95% CI -0.19 to +0.67. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.26 (p 0.298, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.24 (p 0.337, n 18). could be the mix.
- skeptic
- leave-one-out range +0.21 to +0.44, sign flips 0; without severely affected donors +0.30 (p 0.225, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.66 (p 0.0031, n 18) vs +0.30 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MGP in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MGP · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.40 p 0.155 (needs p < 1.8e-4)
Receipts
loading the receipts